O2M Technologies LLC

O2M Technologies LLC is a small, for-profit corporate entity specializing in advanced oxygen imaging technologies, with a primary focus on developing innovative medical imaging solutions for cancer research and regenerative medicine. Registered in SAM.gov since March 2017, the company has established itself as a technology development firm with expertise in electron paramagnetic resonance (EPR) imaging techniques. Their technological innovations center on creating sophisticated imaging methods that can generate precise three-dimensional partial oxygen pressure (pO2) maps of tissues, which have critical applications in understanding and treating cancer, evaluating tissue engineering processes, and developing advanced medical imaging technologies.

Through federal contract awards, O2M Technologies LLC has demonstrated capability in developing specialized medical imaging technologies, specifically through a Small Business Innovation Research (SBIR) program contract with the National Institutes of Health National Cancer Institute. This $455,000 firm fixed-price contract was awarded in September 2021 and focused on building the world's first clinical oxygen imager for cancer treatment. The contract was set aside for total small business participation and involved developing pulse electron paramagnetic resonance technologies to generate 3D pO2 maps of tissues, providing valuable diagnostic and treatment guidance information for cancer researchers and medical professionals.

O2M Technologies LLC has been particularly successful in securing federal grant awards, predominantly from the National Cancer Institute and National Science Foundation. These grants, totaling over $1.5 million, have supported advanced research in oxygen imaging technologies across multiple projects. Key grant objectives have included developing multifunctional imaging instruments capable of simultaneously acquiring tissue oxygen pressure and pH maps, improving single-point imaging acquisition speeds using advanced hardware and deep learning, and creating enabling technologies for noninvasive oxygen imaging in regenerative medicine. The company has also engaged in collaborative sub-grant work with institutions like Dartmouth College and the University of Denver, demonstrating its ability to partner with academic research organizations to advance medical imaging technologies. Their grant work spans critical areas such as cancer detection, tissue engineering, and developing advanced imaging methods that could potentially transform medical diagnostic and treatment approaches.